Phase 1 study of paclitaxel administered twice weekly to children with refractory solid tumors: A Pediatric Oncology Group study

Journal of Pediatric Hematology/Oncology

Volumn 25, Issue 7, 2003, Pages 539-542

  Hayashi, Robert J ^a,e   Blaney, Susan ^b   Sullivan, Jim ^f   Weitman, Steve ^c   Vietti, Teresa ^a   Bernstein, Mark L ^d  

^a ST LOUIS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NONE

Author keywords

Paclitaxel; Pediatric; Phase 1

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL;

ADOLESCENT; ANEMIA; ARTICLE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FEMALE; HEART ARRHYTHMIA; HUMAN; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA;

ANEMIA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NEOPLASMS; NEUTROPENIA; PACLITAXEL; PATIENT SELECTION; PLATELET COUNT;

EID: 0038649085     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200307000-00008     Document Type: Article

References (21)

1. Hainsworth JD, Greco FA. The current role and future prospects of paclitaxel in the treatment of small cell lung cancer. Semin Oncol. 1999;26:60-66.
2. Younes A. Paclitaxel-based treatment of lymphoma. Semin Oncol. 1999;26:123-128.
3. Smith DC, Pienta KJ. Paclitaxel in the treatment of hormone-refractory prostate cancer. Semin Oncol. 1999;26:109-111.
4. Shin DM, Lippman SM. Paclitaxel-based chemotherapy for recurrent and/or metastatic head and neck squamous cell carcinoma: current and future directions. Semin Oncol. 1999;26:100-105.
5. Hudis CA. The current state of adjuvant therapy for breast cancer: focus on paclitaxel. Semin Oncol. 1999;26:1-5.
6. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277:665-667.
7. Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol. 1981;91:479-487.
8. Amos LA, Lowe J. How Taxol stabilises microtubule structure. Chemistry & Biology. 1999;6:R65-R69.
9. Lopes NM, Adams EG, Pitts TW, et al. Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol. 1993;32:235-242.
10. Donaldson KL, Goolsby GL, Wahl AF. Cytotoxicity of the anticancer agents cisplatin and Taxol during cell proliferation and the cell cycle. Int J Cancer. 1994;57:847-855.
11. Liebmann J, Cook JA, Lipschultz C, et al. The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines. Cancer Chemother Pharmacol. 1994;33:331-339.
12. Seibel NL, Reaman GH. New microtubular agents in pediatric oncology. Invest New Drugs. 1996;14:49-54.
13. Sonnichsen DS, Hurwitz CA, Pratt CB, et al. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol. 1994;12:532-538.
14. Hurwitz CA, Relling MV, Weitman SD, et al. Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study. J Clin Oncol. 1993;11:2324-2329.
15. Helson L. Clinical results of a Q4 day × 3 Taxol regimen. Cancer Invest. 1994;12(suppl.1):31-34.
16. Einzig AI, Wiernik PH, Sasloff J, et al. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol. 1992;10:1748-1753.
17. Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer. Inst 1991;83:1797-1805.
18. Arbuck SG, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monographs. 1993:117-130.
19. Perez EA, Vogel CL, Irwin DH, et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2001;19:4216-4223.
20. Markman M, Hall J, Spitz D, et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol. 2002;20:2365-2369.
21. Lilenbaum RC, Schwartz MA, Seigel L, et al. Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma. Cancer. 2001;92:2158-2163.